Investors calmer after Oncolytics explains split of Phase III Reolysin trial
This article was originally published in Scrip
Executive Summary
Oncolytics Biotech saw its US stock price fall by as much as 25.5% on 12 September when the Canadian developer of oncolytic viruses for the treatment of cancer announced that it would double the number of patients enrolled in its Phase III clinical trial for intravenous Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers.